Pancreatic Cancer Research

ResearcherMoffitt Cancer CenterActive in the last 2 years

Jihui Hao

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-1607-1730; OpenAlex author ID A5079537374, A5121069028, A5157896379. Sources: ClinicalTrials.gov.

Their work

Papers
102 (first author 0, last author 69)
Trials
5 (principal investigator on 2)
Grants
0
Labs led
1
Collaborators
205
Papers, trials and grants by year

2011: 1 paper · 2012: 2 papers · 2013: 1 paper · 2014: 8 papers · 2015: 7 papers · 2016: 7 papers, 1 trial · 2017: 5 papers · 2018: 2 papers · 2019: 3 papers · 2020: 2 papers · 2021: 5 papers · 2022: 9 papers · 2023: 12 papers, 2 trials · 2024: 9 papers, 1 trial · 2025: 12 papers · 2026: 17 papers, 1 trial

Papers 50 of 102

  1. Mitochondrial Calcium Uniporter Drives Chemoresistance in Pancreatic Cancer via Glutathione-Mediated Stemness Maintenance. Co-author DOI 10.1002/advs.202507346↗
  2. Tumor-Derived Interleukin 35 Promotes Fibrosis in the Tumor Microenvironment of Pancreatic Cancer by Activating Pancreatic Stellate Cells. Co-author DOI 10.1002/advs.202509074↗
  3. Pathomics Signature for Prognosis and CA19-9 Interception in Pancreatic Ductal Adenocarcinoma: A Real-Life, Multi-Center Study. Co-author DOI 10.1002/advs.202515952↗
  4. Retraction Note: BICC1 drives pancreatic cancer progression by inducing VEGF-independent angiogenesis. Last author DOI 10.1038/s41392-025-02561-9↗
  5. Targeting GPR34 in damage-associated macrophages enhances anti-tumor immunity and the efficacy of Surufatinib in pancreatic cancer. Last author DOI 10.1038/s41392-026-02641-4↗
  6. Exosomal miR-92a-3p promotes pancreatic cancer cells' extravasation by inducing vascular permeability through inhibition of DAB2IP. Co-author DOI 10.1038/s41419-026-08719-9↗
  7. NALIRIFOX versus gemcitabine plus nab-paclitaxel in Chinese patients with advanced pancreatic adenocarcinoma: a randomized, open-label phase II trial. Last author DOI 10.1038/s41467-026-68409-0↗
  8. CAF-derived PAI-1 serves as an EGFR ligand and fuels KRAS-mutant pancreatic cancer. Last author DOI 10.1038/s41467-026-75132-3↗
  9. Rationally and in silico guided APOBEC3F-directed CBE for enhanced PDAC genetic therapy. Co-author DOI 10.1038/s42003-026-09770-0↗
  10. Trogocytosis-orchestrated CLDN18.2-"dressed" CD8+ T cells drive pancreatic cancer progression via glucose metabolic reprogramming-induced cytotoxicity debilita… Last author DOI 10.1136/gutjnl-2025-335790↗
  11. KRAS mutation-driven O-GlcNAcylation of CLDN18.2 enhances the progression of pancreatic cancer and reduces the efficacy of CLDN18.2-targeted therapy. Last author DOI 10.1136/gutjnl-2025-336277↗
  12. Short-term risk prediction model for pancreatic cancer in type 2 diabetes: development and validation across two independent Chinese cohorts. Last author DOI 10.1136/gutjnl-2026-339722↗
  13. Chemotherapy Reawakens Dormant Disseminated Pancreatic Cancer Cells in the Liver by Promoting Senescent Hepatocyte-Induced Neutrophil Extracellular Traps. Co-author DOI 10.1158/0008-5472.can-26-0151↗
  14. Development and Prospective Validation of a Cell-free DNA-Based Model for the Early Detection of Pancreatic Cancer. Last author DOI 10.1158/2159-8290.cd-25-0323↗
  15. Senescent Cancer-Associated Fibroblasts Drive Early-Stage Lymph Node Metastasis in Pancreatic Cancer through Lactate-Mediated Metabolic-Epigenetic Rewiring. Last author DOI 10.1158/2159-8290.cd-25-1627↗
  16. Sequential nimotuzumab plus gemcitabine and nab-paclitaxel chemotherapy followed by irreversible electroporation in advanced pancreatic ductal adenocarcinoma: … Last author DOI 10.20892/j.issn.2095-3941.2025.0848↗
  17. Research on precision treatment of pancreatic cancer targeted by antibody-drug conjugates. Last author DOI 10.5582/bst.2025.01271↗
  18. Targeting Mast Cell Activation and MIF-Mediated Remodelling Enhances Chemotherapy Response in Pancreatic Cancer. Last author DOI 10.1002/advs.202509930↗
  19. The nuclear condensates of ESE3/EHF induce cellular senescence without the associated inflammatory secretory phenotype in pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.canlet.2024.217408↗
  20. A CD147-targeted small-molecule inhibitor potentiates gemcitabine efficacy by triggering ferroptosis in pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.xcrm.2025.102292↗
  21. Nociceptor neurons promote PDAC progression and cancer pain by interaction with cancer-associated fibroblasts and suppression of natural killer cells. Last author DOI 10.1038/s41422-025-01098-4↗
  22. Targeting TNK2/ACK1 reverses the immunosuppressive tumor microenvironment and synergizes with immunochemotherapy in pancreatic cancer. Last author DOI 10.1038/s41467-025-67197-3↗
  23. Adaptation to cystine limitation stress confers a targetable lipid metabolism vulnerability in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41467-025-68099-0↗
  24. Hypoxic and Acidic Tumor Microenvironment-Driven AVL9 Promotes Chemoresistance of Pancreatic Ductal Adenocarcinoma via the AVL9-IκBα-SKP1 Complex. Last author DOI 10.1053/j.gastro.2024.10.042↗
  25. Endothelial-like cancer-associated fibroblasts facilitate pancreatic cancer metastasis via vasculogenic mimicry and paracrine signalling. Co-author DOI 10.1136/gutjnl-2024-333638↗
  26. Novel Pt@PCN-Cu-induced cuproptosis amplifies αPD-L1 immunotherapy in pancreatic ductal adenocarcinoma through mitochondrial HK2-mediated PD-L1 upregulation. Co-author DOI 10.1186/s13046-025-03409-4↗
  27. Safety and efficacy of intraoperative radiation therapy using a low-energy X-ray source for resectable pancreatic cancer: an interim evaluation of an ongoing p… Last author DOI 10.20892/j.issn.2095-3941.2024.0287↗
  28. Integrated pretreatment stratification system for pancreatic cancer: combining anatomical resectability and tumor biological parameters. Last author DOI 10.20892/j.issn.2095-3941.2025.0213↗
  29. Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer. Co-author DOI 10.3791/67413↗
  30. Survival outcomes of adjuvant chemotherapy in patients with stage I pancreatic cancer stratified by pathologic risk. Last author DOI 10.1016/j.surg.2024.07.047↗
  31. Tumor-derived interleukin 35 mediates the dissemination of gemcitabine resistance in pancreatic adenocarcinoma. Co-author DOI 10.1038/s41388-024-02938-0↗
  32. Correction: BICC1 drives pancreatic cancer progression by inducing VEGF-independent angiogenesis. Last author DOI 10.1038/s41392-023-01721-z↗
  33. Targeting ESE3/EHF With Nifurtimox Inhibits CXCR2+ Neutrophil Infiltration and Overcomes Pancreatic Cancer Resistance to Chemotherapy and Immunotherapy. Last author DOI 10.1053/j.gastro.2024.02.046↗
  34. Integrating tertiary lymphoid structure-associated genes into computational models to evaluate prognostication and immune infiltration in pancreatic cancer. Last author DOI 10.1093/jleuko/qiae067↗
  35. BICC1 drives pancreatic cancer stemness and chemoresistance by facilitating tryptophan metabolism. Last author DOI 10.1126/sciadv.adj8650↗
  36. CD64+ fibroblast-targeted vilanterol and a STING agonist augment CLDN18.2 BiTEs efficacy against pancreatic cancer by reducing desmoplasia and enriching stem-l… Last author DOI 10.1136/gutjnl-2024-332371↗
  37. Prognostic significance of grade of malignancy based on histopathological differentiation and Ki-67 in pancreatic ductal adenocarcinoma. Last author DOI 10.20892/j.issn.2095-3941.2023.0363↗
  38. Clinical outcomes of second-line chemotherapy in patients with advanced pancreatic adenocarcinoma: a real-world study. Co-author DOI 10.20892/j.issn.2095-3941.2024.0036↗
  39. CD73, a Promising Therapeutic Target of Diclofenac, Promotes Metastasis of Pancreatic Cancer through a Nucleotidase Independent Mechanism. Last author DOI 10.1002/advs.202206335↗
  40. Retraction notice to "HIF-1α mediates tumor-nerve interactions through the up-regulation of GM-CSF in pancreatic ductal adenocarcinoma" [Cancer Lett. 453 (2019… Last author DOI 10.1016/j.canlet.2023.216059↗
  41. A new staging system for postoperative prognostication in pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.isci.2023.107589↗
  42. BICC1 drives pancreatic cancer progression by inducing VEGF-independent angiogenesis. Last author DOI 10.1038/s41392-023-01478-5↗
  43. Survival outcomes of neoadjuvant therapy followed by radical resection versus upfront surgery for stage I-III pancreatic ductal adenocarcinoma: a retrospective… Last author DOI 10.1097/js9.0000000000000425↗
  44. Selective extended dissection for pancreaticoduodenectomy is associated with better survival in pancreatic cancer patients: retrospective cohort study. Co-author DOI 10.1097/js9.0000000000000437↗
  45. SDCBP promotes pancreatic cancer progression by preventing YAP1 from β-TrCP-mediated proteasomal degradation. Last author DOI 10.1136/gutjnl-2022-327492↗
  46. Nuclear GRP78 Promotes Metabolic Reprogramming and Therapeutic Resistance in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-23-1143↗
  47. Irbesartan overcomes gemcitabine resistance in pancreatic cancer by suppressing stemness and iron metabolism via inhibition of the Hippo/YAP1/c-Jun axis. Co-author DOI 10.1186/s13046-023-02671-8↗
  48. Combination of RUNX1 inhibitor and gemcitabine mitigates chemo-resistance in pancreatic ductal adenocarcinoma by modulating BiP/PERK/eIF2α-axis-mediated endopl… Last author DOI 10.1186/s13046-023-02814-x↗
  49. Artificial intelligence-based comprehensive analysis of immune-stemness-tumor budding profile to predict survival of patients with pancreatic adenocarcinoma. Last author DOI 10.20892/j.issn.2095-3941.2022.0569↗
  50. Nuclear PLD1 combined with NPM1 induces gemcitabine resistance through tumorigenic IL7R in pancreatic adenocarcinoma. Last author DOI 10.20892/j.issn.2095-3941.2023.0039↗

Trials 5

  1. Baduanjin for Quality of Life in Pancreatic Cancer Chemotherapy Principal investigator NCT07791550↗
  2. Nimotuzumab Combined With GX as Postoperative Adjuvant Therapy in Pancreatic Cancer Study chair NCT06409429↗
  3. A Preoperative Model to Predict the Lymphovascular Invasion in Pancreatic Ductal Adenocarcinoma Study chair NCT05997147↗
  4. Nimotuzumab Plus AG in Pancreatic Cancer With Liver Metastasis Study chair NCT06405685↗
  5. Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of Pancreatic Cancer Principal investigator NCT03236883↗

Closest collaborators

The 25 strongest of 205 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xiuchao Wang · 53 shared papers, 2011–2026 · strength 6.46
  2. Tiansuo Zhao · 48 shared papers, 2011–2026 · strength 6.09
  3. Chongbiao Huang · 38 shared papers, 2015–2026 · strength 5.10
  4. Song Gao · 37 shared papers, 2012–2026 · strength 4.55
  5. Tianxing Zhou · 22 shared papers, 2019–2026 · strength 4.14
  6. Yongjie Xie · 20 shared papers, 2022–2026 · strength 3.73
  7. Shengyu Yang · 29 shared papers, 2014–2026 · strength 3.59
  8. Chuntao Gao · 16 shared papers, 2014–2026 · strength 2.60
  9. Jing Liu · 17 shared papers, 2019–2026 · strength 2.59
  10. Yukuan Feng · 10 shared papers, 2024–2026 · strength 2.10
  11. Jun Yu · 9 shared papers, 2024–2026 · strength 1.86
  12. Yiping Zou · 9 shared papers, 2023–2026 · strength 1.72
  13. Huizhi Sun · 10 shared papers, 2021–2026 · strength 1.65
  14. Chao Xu · 8 shared papers, 2017–2026 · strength 1.44
  15. Zengxun Li · 9 shared papers, 2017–2026 · strength 1.17
  16. Weishuai Liu · 6 shared papers, 2021–2026 · strength 1.10
  17. Wenna Jiang · 8 shared papers, 2017–2026 · strength 1.10
  18. Chao Yang · 5 shared papers, 2025–2026 · strength 1.05
  19. He Ren · 18 shared papers, 2011–2021 · strength 1.03
  20. Yuexiang Liang · 5 shared papers, 2023–2026 · strength 1.00
  21. Danqi Fu · 7 shared papers, 2019–2025 · strength 0.99
  22. Shaofei Chang · 5 shared papers, 2023–2025 · strength 0.98
  23. Liangliang Wu · 7 shared papers, 2019–2026 · strength 0.98
  24. Quan Man · 5 shared papers, 2023–2025 · strength 0.92
  25. Rui Liu · 4 shared papers, 2025–2026 · strength 0.91

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.